Key Takeaway: The article reports on the first use of deep transcranial magnetic stimulation (dTMS) with an H7 coil in an adolescent suffering from treatment-resistant obsessive-compulsive disorder (OCD). After 10 sessions, the patient showed significant clinical improvement, which was well tolerated. The benefits were maintained during a one-month follow-up, indicating the treatment's safety and efficacy.
Price reaction · baseline $2.49 (2023-11-21 close) · hit pre-market · 7 other BWAY headline(s) in the window, move may be shared
day 0 close
+10.6%
day 1
+17.1%
day 3 · peak
+23.9%
Market Sentiment Analysis
POSITIVE FACTORS
First application of dTMS using H7 coil in adolescents.
Significant clinical improvement after 10 sessions.
Well-tolerated treatment for childhood-onset OCD.
Sustained benefits observed during one-month follow-up.
Full Press Release Details
Summary:
We describe the first instance of dTMS application using H7 coil in an adolescent for childhood-onset OCD to evaluate the safety and efficacy of dTMS as an add-on treatment leading to the rapid and significant clinical improvement shown after 10 sessions in a patient with treatment-resistant OCD which was well tolerated; furthermore, the clinical benefits were sustained during a short-term follow-up in one month. dTMS with the H7 over the mPFC-ACC was found to be a safe and effective treatment.
Full Article:
Frequently Asked Questions
What is dTMS?
Deep transcranial magnetic stimulation (dTMS) is a non-invasive treatment method.
How many sessions of dTMS were administered?
The patient received 10 sessions of dTMS treatment.
What condition was treated in the case report?
The case report focused on treatment-resistant obsessive-compulsive disorder (OCD).
Was the treatment well tolerated?
Yes, the dTMS treatment was well tolerated by the patient.
Were the clinical benefits sustained?
Yes, the clinical benefits were sustained during a one-month follow-up.